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(EORTC QLQ-C30 & H&N35), and penetration aspiration scale 
(PAS) scores for modified barium swallow studies. 
 
Results: The study population is 43 patients. The pCR rate 
was 86% (37/43). All 6 non-pCR cases were limited to 
microscopic foci of residual cancer: 1 primary site, 5 nodal. 
All patients are alive with no evidence of disease (median 
follow-up 21.3 months, range 4-41 months). Thirty-eight 
patients had a follow-up of at least one year. The incidence 
of acute CTCAE Grade 3/4 toxicity and PRO-CTCAE 
severe/very severe symptoms were: mucositis 34%/45%, pain 
5%/48%, nausea 18%/52%, vomiting 5%/34%, dysphagia 
39%/55%, and xerostomia 2%/75%. Grade 3/4 hematological 
toxicities were 11%. Mean pre and 6 month post CRT EORTC 
QOL scores were: Global 80/71 (lower worse), Pain (mouth, 
jaw, throat) 19/21 (higher worse), Swallowing 11/16, 
Coughing 17/26, Dry Mouth 16/68, and Sticky Saliva 6/49. Six 
months post CRT mean PRO-CTCAE scores for swallowing and 
dry mouth were mild and moderate, respectively. No patients 
reported their swallowing or dry mouth symptoms to be 
severe or very severe. 39% of patients required a feeding 
tube (none permanent) for a median of 15 weeks (5 - 22 
weeks). There were no significant differences in PAS scores 
for thin, pureed, and solid foods before and after CRT. 
 
Conclusion: Pathological CR rate with decreased intensity of 
therapy with 60 Gy of IMRT and weekly low-dose cisplatinum 
is very high in favorable risk OPSCC with evidence of 
decreased toxicity compared to standard therapies. 
(ClinicalTrials.gov, NCT01530997) 
 
OC-0454  
Clinical outcome in nasopharyngeal carcinoma patients 
with post-radiation detectable plasma EBV DNA 
J.C. Lin
1Taichung Veterans General Hospital, Department of 
Radiation Oncology, Taichung, Taiwan 
1, W.Y. Wang2, C.W. Twu3 
2Hung Kuang University, Department of Nursing, Taichung, 
Taiwan 
3Taichung Veterans General Hospital, Department of 
Otorhinolaryngology, Taichung, Taiwan 
 
Purpose or Objective: To investigate the long-term clinical 
behavior of nasopharyngeal carcinoma (NPC) patients with 
persistently detectable plasma EBV (pEBV) DNA after curative 
radiotherapy (RT) with/without chemotherapy. 
 
Material and Methods: We screened 931 newly diagnosed 
NPC patients who finished curative RT and found 125 patients 
(13.4%) with detectable pEBV DNA one week after finishing 
RT. The clinical characteristics, treatment modality, 
subsequent failure patterns and survivals were analyzed. 
 
Results: The levels of post-RT pEBV DNA for the studied 
population were in a very lower copy number (median 21, 
interquartile range 8-206 copies/mL). After a minimal follow-
up of 52 months, the subsequent relapse rate was 64.8% 
(81/125) with distant failure predominantly and the median 
time to progression is 20 months for all 125 patients. Thirty-
two of 39 (82.1%) patients with post-RT pEBV DNA ³ 100 
copies/ml developed tumor relapse later, whereas 57.0% 
(49/86) patients with post-RT pEBV DNA < 100 copies/ml had 
tumor relapse (P=0.0065). The 5-year rates of overall survival 
(OS) were 20.5% and 62.9% for the patients with post-RT viral 
load ³ and < 100 copies/mL (HR, 0.22; 95% CI, 0.12 to 0.38; 
P<0.0001). Patients who received adjuvant chemotherapy 
(AdjCT) with oral tegafur-uracil experienced significant 
reduction in distant failures (66.2% vs. 31.6%; P=0.0001) but 
similar locoregional recurrences (P=0.234). The 5-year OS 
rates were 69.4% for the patients who received AdjCT 
compared with 33.2% for those of without AdjCT (HR, 0.38; 
95% CI, 0.24 to 0.61; P<0.0001). 
 
Conclusion: NPC patients with persistently detectable pEBV 
DNA after finishing RT have a higher rate of treatment 
failure. Levels of the post-RT pEBV DNA and administration of 
AdjCT affect the final outcome. Future trial should consider 
post-RT pEBV DNA levels as a stratification factor and 
investigate the role of AdjCT for the target population. 
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Purpose or Objective: Proton therapy is a form of 
radiotherapy that can be concentrated on a tumor using a 
scanned or modulated Bragg peak. To use this radiotherapy 
efficiently in a clinical context, it is necessary to evaluate 
the clinical proton-irradiated volume accurately. Therefore, 
a beam ON-LINE PET system (BOLPs) has been developed for 
activity imaging of various positron emitter nuclei generated 
from each target nucleus by target nuclear fragment 
reactions with irradiated proton beam. The purpose of this 
study is to develop an activity pencil beam (APB) algorithm 
for a simulation system for proton activated positron-
emitting imaging in proton therapy. 
 
 
 
Material and Methods: The APB algorithm was developed as 
a calculation algorithm of the activity distributions formed by 
positron emitter nuclei generated from target nuclear 
fragment reactions. Depth activity data of 12C nuclei, 16O 
nuclei, and 40Ca nuclei were measured with BOLPs after 
proton beam irradiation whose energies were 138, 179, and 
223 MeV. Measurement time was about 5 h until the 
measured activity reached the background level.  
